All content for Oncology Brothers: Practice-Changing Cancer Discussions is the property of Oncology Brothers and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Managing Toxicities of CDK4/6 Inhibitors in Hormone Positive Breast Cancer - Dr. Stephanie Graff
Oncology Brothers: Practice-Changing Cancer Discussions
22 minutes
3 weeks ago
Managing Toxicities of CDK4/6 Inhibitors in Hormone Positive Breast Cancer - Dr. Stephanie Graff
In this episode of Oncology Brothers, we dived deep into the world of CDK4-6 inhibitors, focusing on their side effects and management in breast cancer treatment. Joined by an esteemed guest, Dr. Stephanie Graff, a medical breast oncologist from Brown University Health. We explored the side effects and management strategies for three commonly used CDK4/6 inhibitors: ribociclib, abemaciclib, and palbociclib.
Key topics discussed include:• The evolving role of CDK4/6 inhibitors in early breast cancer and adjuvant settings.• Detailed management of side effects such as QT prolongation, liver function tests, and diarrhea.• The importance of shared decision-making with patients regarding treatment options.• Insights into the latest clinical trial data and its implications for practice.
Whether you're a healthcare professional or someone interested in oncology, this episode provides valuable insights into optimizing patient care while managing the complexities of CDK4-6 inhibitors.
Follow us on social media:• X/Twitter: https://twitter.com/oncbrothers• Instagram: https://www.instagram.com/oncbrothers• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and check out our other episodes for more discussions on oncology treatments and patient management strategies!
#CDK4/6inhibitors #BreastCancer #Ribociclib #Abemaciclib #Palbociclib #OncologyBrothers #SideEffectManagement #HRpositiveBC
Oncology Brothers: Practice-Changing Cancer Discussions
